At a glance
ClinicalIndex Comparison RecordN/ACompleted· 5,115 enrolled
Drug / intervention
No interventionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
ATORVASTATIN EFFECTIVENESS AND SAFETY IN CARDIOLOGY PATIENTS IN REAL WORLD SETTING: A REGISTRY STUDY IN CHINA
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Oct 1, 2015·Updated Feb 21, 2021
In Brief
An observational study evaluating No intervention for Coronary Artery Disease, Hypercholesterolemia, Hypertension. Completed, enrolled 5,115 participants across 54 sites.
Detailed Summary
The study is to verify atorvastatin effectiveness and safety in Chinese population, and explore the optimal atorvastatin regimens in high-to-moderate risk for ASCVD。
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 2015
Enrollment StartJun 2016
Primary CompletionAug 2018
TodayJul 2026
First PostedOct 1, 2015
Enrollment StartJun 22, 2016
Primary CompletionAug 31, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.8 years ago
Interventions
No interventionother
Because this is a non-interventional study, there is no intervention here.